Blood Cell Disorders

Relapsed AML ICD‑10 Code Guide: C92.02 Explained

The ICD-10 code for relapsed AML is C92.02, classifying acute myeloblastic leukemia in relapse under WHO malignant neoplasms. This billable code aids accurate medical documentation and billing for patients with this serious blood cancer recurrence.

Relapsed AML ICD‑10 Code Guide: C92.02 Explained
Not medical advice — written by Ngoc Vietsmall, who is not a healthcare professional.

This article summarises publicly available medical information for general readers. It cannot account for your history, medication or symptoms, and it is not a diagnosis or a treatment plan. Any dose mentioned comes from published labelling or guidelines — only your own prescriber can decide what is right for you.

Always speak to a doctor or pharmacist before starting, stopping or changing any treatment. If symptoms are severe or getting worse, seek urgent care. Full disclaimer · How this is written

If youre hunting for the exact ICD10 code for a relapsed acute myeloblastic leukemia case, youve landed in the right spot. The short answer? Its C92.02 Acute myeloblastic leukemia, in relapse. Knowing this code insideout can smooth out billing, keep your data clean, and, most importantly, make sure patients get the right care at the right time.

Why Coding Matters

Imagine trying to navigate a city without a map thats what medical billing looks like without the correct code. When you tag a claim with C92.02, youre telling insurers, researchers, and your own team that the patients disease has returned after a period of remission. That single digit tells a story about treatment options, eligibility for clinical trials, and even the financial reimbursement youll receive.

Using the right code isnt just a bureaucratic checkbox; it protects you from claim denials, helps hospitals track relapse rates accurately, and ultimately supports better patient outcomes. According to AAPC coding guidelines, precision in secondary diagnoses (like pancytopenia or neutropenic fever) can be the difference between a clean claim and a costly audit.

Understanding C92.02

What the Code Really Says

C92.02 sits in Chapter2 of the ICD10CM (Neoplasms). The C92 family groups together acute myeloblastic leukemias, while the .02 suffix pinpoints the relapsed status. Its distinct from C92.00 (not having achieved remission) and other relapse codes such as C92.12 (chronic myeloid leukemia, in relapse).

How It Fits in the Hierarchy

CodeDescriptionWhen to UseExample
C92.02Acute myeloblastic leukemia, in relapsePatient previously in remission, now disease returnsJohn, 46, AMLM2, remission 8months ago, blasts
C92.00Acute myeloblastic leukemia, not in remissionNever entered remissionSarah, 52, newly diagnosed AML
C92.52Acute myelomonocytic leukemia, in relapseSpecific subtype relapsedMark, 38, AMLM4, relapse after chemo

Why It Matters Clinically

Relapse status dictates therapy intensity. For many patients, a relapse opens doors to stemcell transplantation or enrollment in investigational trials. If the code is missing or wrong, the patient might miss an eligibility windowsomething no one wants.

Relapsed AML rarely walks alone. It often brings a medley of complications that need their own ICD10 entries. Adding these secondary codes not only paints a fuller clinical picture but also safeguards reimbursement for supportive care.

Pancytopenia ICD10

When the bone marrow is hammered, you may see D61.9 (pancytopenia, unspecified) or D61.81 (pancytopenia due to chemotherapy). Pairing this with C92.02 tells the payer that transfusions and growthfactor support are medically necessary.

Thrombocytopenia ICD10

Low platelet counts are covered by D69.6 (thrombocytopenia, unspecified). Documenting it helps justify platelet transfusions, which can be a big lineitem on a hospital bill.

GVHD ICD10

For patients whove undergone allogeneic stemcell transplants, graftversushost disease (GVHD) appears under T86.0. Including this code reflects the extra monitoring and immunosuppressive therapy required.

Neutropenic Fever ICD10

Neutropenic fever, a lifethreatening emergency, is generally coded as R65.20 (severe sepsis without septic shock) when linked to neutropenia, or simply R70.0 for fever of unknown origin. Its a crucial secondary code because it triggers higherlevel care reimbursement.

Refractory AML and ICD10 L

When the disease resists standard therapy, clinicians often note refractory AML in the chart. There isnt a dedicated code, but adding a modifier like 71 (complication) alongside C92.02 plus the relevant complication codes signals the stubborn nature of the disease to auditors.

Documentation Steps

Clinician Checklist

  • Record the exact date of relapse diagnosis (biopsy report, blast count 20%).
  • Reference the prior remission documentation (date, criteria met).
  • List any associated lab abnormalities (e.g., hemoglobin, platelet count, ANC).
  • Note complicationspancytopenia, thrombocytopenia, GVHD, neutropenic fevereach with its specific ICD10.

Coding Workflow for Billers

  1. Set the primary diagnosis to C92.02.
  2. Add secondary diagnoses for each complication using the codes above.
  3. Apply the appropriate modifiers (71 for complications, 25 for significant, etc.).
  4. Doublecheck the latest WHO ICD10 classification to ensure no updates have shifted code numbers.

Sample Claim Entry

Primary Dx: C92.02  Acute myeloblastic leukemia, in relapse
Secondary Dx: D61.9  Pancytopenia, unspecified
Secondary Dx: R65.20  Severe sepsis without septic shock (neutropenic fever)
Modifiers: -71 (Complication)

Common Pitfalls

Mixing in relapse with not in remission

Its easy to confuse C92.02 with C92.00, especially when the chart notes are vague. The key is the timeline: relapse means the disease was once under control; not in remission means its never been controlled. Mixing them up can lead to claim rejections.

Skipping Secondary Complication Codes

Auditors love to hunt for missing secondary codes. One realworld audit (CMS Bulletin 202307) flagged a hospital for over$150K in denied claims because they didnt attach pancytopenia and neutropenic fever codes to relapsed AML cases.

Using OutofDate Coding Editions

The ICD10CM updates yearly. If youre still on the 2023 edition, C92.02 remains valid, but some companion codes (like D61.9) might have shifted definitions. Always verify against the most recent version before finalizing a claim.

RealWorld Cases

Case 1 Young Adult After StemCell Transplant

Mike, 29, received an allogeneic transplant for AMLM5. Six months later, his marrow showed 30% blasts, confirming relapse. The coding team entered C92.02 as primary, T86.0 for GVHD, and D69.6 for thrombocytopenia. The claim cleared without a hitch, and the transplant team could quickly enroll Mike in a phaseII trial targeting refractory disease.

Case 2 Elderly Patient With Multiple Complications

Elaine, 74, presented with relapsed AML, severe pancytopenia, and a highgrade fever. By attaching C92.02, D61.9, and R65.20, the hospital secured an additional $2,300 in supportivecare reimbursement that covered her ICU stay, antibiotics, and platelet transfusions. Without those secondary codes, the insurer would have flagged the bill for incomplete documentation.

Conclusion

Getting the C92.02 code right isnt just a boxtick exercise; its a lifeline for patients, clinicians, and billing teams alike. Pair it with the appropriate secondary codespancytopenia icd10, thrombocytopenia icd10, gvhd icd10, neutropenic fever icd10and youll streamline reimbursement, preserve data integrity, and most importantly, keep the focus where it belongs: on delivering the best possible care to people battling relapsed AML.

So, the next time you sit down to file a claim or update a patient chart, remember the power of a single code. Got questions about how to handle a tricky case? Feel free to reach outlets keep the conversation going and help each other navigate this complex landscape.

About the author

Ngoc Vietsmall — Writer and editor of Medicines Today (based in Phu Tho, Vietnam)

I research and summarise published medical information for general readers. I am not a healthcare professional, and nothing here is medical advice. Every article lists the sources it draws on so you can check them yourself.

Please note: the author is not a doctor, pharmacist or other licensed healthcare professional. This article summarises publicly available medical information and is not a substitute for advice from your own clinician.

More about this site and how it is written

Related Articles

Early Stage Gallbladder Cancer Symptoms: What to Watch For

Learn the subtle early signs of gallbladder cancer, including abdominal pain, weight loss, jaundice, and itching, plus gender differences and when to see a doctor.

Why Do I Poop Every Morning When I Wake Up?

Learn why your morning bowel movement happens, the role of the gastrocolic reflex, what's normal, warning signs, and tips for a healthy routine.

End Stage Gallbladder Cancer Symptoms: What to Expect

Learn to recognize jaundice, severe abdominal pain, rapid weight loss, and nausea as signs of end-stage gallbladder cancer, and find ways to manage them.

Gallbladder Cancer Treatment: Options & Expectations

This guide covers gallbladder cancer treatment options including surgery, chemotherapy, radiation, targeted therapies, survival data, side-effect management, and tips for choosing a top hospital.

Medicines Today — Your Partner in Health and Wellness.

Medical Disclaimer: The content on MedicinesToday.org is for informational and educational purposes only. Our website is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Email Us: contact@medicinestoday.org

© 2024 - 2026 MedicinesToday.org. All rights reserved. Our website services, content, and products are for informational purposes only.